Additionally, these results underscore TREK-1 activation as a promising intervention to modulate adipocyte expansion, reduce lipid accumulation, and attenuate metabolic disturbances associated with obesity and insulin resistance. Here, KCNK2 is linked to obesity due to melanocortin 4 receptor deficiency.